Lead Product(s): Rifamycin
Therapeutic Area: Gastroenterology Product Name: Aemcolo
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: RedHill Biopharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2021
The trial investigated the efficacy and safety of two doses of Rifamycin SV-MMX 600mg against placebo after a 2-week course of treatment followed by a 3 months follow-up.